Previous 10 | Next 10 |
Indaptus Therapeutics (INDP) +22% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors. Zealand Pharma (ZEAL) +19% announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism. CBAK Energy Technology (CBAT)...
Wall Street finished with a mixed performance on Monday, as the major averages wound their way through another uncertain session. The S&P 500 and Nasdaq lost ground, while the Dow posted a fractional gain. While most market segments ended the day lower, the energy sector remained a source...
A poorly received decision from the management team at Chimerix (NASDAQ: CMRX) , a biopharmaceutical company, sent its stock price into a nosedive on Monday morning. Investors furious about the sale of Tembexa for an uncertain sum and the company's plans for that cash infusion have ...
Chimerix's (NASDAQ:CMRX) stock fell ~37% premarket May 16 after Emergent BioSolutions (NYSE:EBS) said it was acquiring exclusive worldwide rights to Chimerix's smallpox antiviral Tembexa. Under the agreement, Emergent will pay Chimerix $225M upfront in cash upon closing and up ...
Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threat Transaction to be funded with currently available funds; Expected to be accretive beginning with ...
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VI...
Contract vaccine manufacturer Emergent BioSolutions (NYSE:EBS) was forced to destroy 400M doses of COVID-19 vaccine due to contamination issues, a figure far higher than previously disclosed. In a report from the House Oversight and Reform Committee, a communication from an Emergent quality c...
Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q1 2022 Earnings Call Apr 28, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q1 2022 Earnings Call Transcript
The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Emergent BioSolutions Inc. 2022 Q1 - Results - Earnings Call Presentation
Emergent BioSolutions (NYSE:EBS) trades lower during the day's trade after Cowen lowered price target to $30 from $40 while maintaining its Market Perform rating on the shares. Analyst Boris Peaker noted the anthrax vaccine and Narcan revenues were ahead of guidance but Narcan is likely to sh...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...